IsoPlexis, which provides a single cell proteomics platform for drug development, filed on Tuesday with the SEC to raise up to $100 million.
IsoPlexis believes its platform, which includes instruments, chip consumables, and software, is the first to employ both proteomics and single cell biology in an effort to fully characterize and link cellular function to patient outcomes by revealing treatment response and disease progression. Since its commercial launch in June 2018, the company's platform has been adopted by the top 15 global biopharmaceutical companies by revenue and nearly half of the comprehensive cancer centers in the US. IsoPlexis' initial focus has been on developing applications for cancer immunology and cell and gene therapy, but it is now expanding its capabilities to include applications for infectious diseases, inflammatory conditions, and neurological diseases.
The Branford, CT-based company was founded in 2013 and booked $12 million in revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol ISO. IsoPlexis filed confidentially on May 13, 2021. Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
